Close Menu

Essure Birth Control

Essure birth control coil implant has been linked to serious and dangerous side effects. CNN covered the story of the death of a baby after Essure was implanted in the mother to prevent conception. See the CNN video: FDA mandates new warnings, new data for Essure contraceptive device.  Over 5,000 women filed grievances with the FDA between November 2002 and May 2015, complaining of severe pain and bleeding, perforation, unintended pregnancies, miscarriages, stillbirths after an Essure coil was implanted in the Fallopian tubes.

FDA Black Box Warning Added

A new “black box warning” label for Essure to call attention to serious or life-threatening risks was added in 2016. Approved by the FDA in 2002, Essure, manufactured by Bayer and composed of metallic coils and polyester fibers, is a permanent form of birth control in which a coil is non-surgically placed into a woman’s fallopian tubes.  When implanted, the fibers and coils provoke inflammation and scar tissue which block entrance to the sperm reaching the egg. Essure has been removed from the market in other countries, but is still being implanted in U.S. women.

Essure has been linked to multiple dangerous side effects including:

  • Hemorrhage
  • Birth defects caused by nickel poisoning
  • Ectopic pregnancy
  • Premature birth due to membranes ruptured by loose coils
  • Unintended pregnancy
  • Miscarriage
  • Migration of the device
  • Malposition of the device
  • Fracture or breakage of the device
  • Incompatibility from nickel allergies

Over 3700 women have filed claims and lawsuits are consolidated in Pennsylvania before Judge John R. Padova and in California before Judge Winifred Y. Smith.  To date, there has been no mass settlement of Essure cases.

Free Medical Legal Consultation

If you or a loved one has or have had Essure permanent birth control implanted and experienced serious life-threatening complications, contact us for a free medical legal consultation at 1-800-814-4540 or or fill out our contact form.

Share This Page:
Facebook Twitter LinkedIn Google Plus